XORTX discloses US$240,000 finder’s fees tied to Vectus renal program acquisition after omission
X
XRTX• Corrective disclosure on Vectus acquisition fees
XORTX issued a corrective disclosure on its April 13, 2026 acquisition of Vectus Biosystems’ Renal Anti-Fibrotic Therapeutic Program.
Aggregate cash finder’s fees of USD 240,000 were paid in connection with the transaction.
The finder’s fee disclosure was inadvertently omitted from the April 13, 2026 closing announcement.
•
XORTX discloses US$240,000 finder’s fees tied to Vectus renal program acquisition after omission - XRTX News | Rallies
